Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report.

Buchner D, Hieggelke L, Löser H, Bruns CJ, Quaas A, Ghadimi MPH.

BMC Cancer. 2018 Dec 12;18(1):1243. doi: 10.1186/s12885-018-5151-6.

2.

Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma.

Mersch S, Riemer JC, Schlünder PM, Ghadimi MP, Ashmawy H, Möhlendick B, Topp SA, Arent T, Kröpil P, Stoecklein NH, Gabbert HE, Knoefel WT, Krieg A.

Tumour Biol. 2016 Feb;37(2):2341-51. doi: 10.1007/s13277-015-4050-6. Epub 2015 Sep 15.

PMID:
26373732
3.

[Multimodal management in soft tissue sarcoma of the trunk and extremities].

Ghadimi MP, Rehders A, Knoefel WT.

Chirurg. 2014 May;85(5):378-82. doi: 10.1007/s00104-013-2690-x. Review. German.

PMID:
24733613
4.

Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection?

Tseng WW, Madewell JE, Wei W, Somaiah N, Lazar AJ, Ghadimi MP, Hoffman A, Pisters PW, Lev DC, Pollock RE.

Ann Surg Oncol. 2014 Jul;21(7):2136-43. doi: 10.1245/s10434-014-3643-4. Epub 2014 Apr 7.

PMID:
24705628
5.

Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations.

Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres K, Colombo C, Peng T, Lusby K, Ingram D, Hornick JL, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE.

Cancer. 2013 May 15;119(10):1868-77. doi: 10.1002/cncr.27847. Epub 2013 Feb 7.

6.

Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, Lazar AJ, Hunt KK, Anderson ML, Creighton CJ, Lev D, Pollock RE.

Ann Surg Oncol. 2013 Jul;20(7):2364-72. doi: 10.1245/s10434-012-2834-0. Epub 2013 Jan 20.

7.

Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2012 Aug;11(8):1758-69. doi: 10.1158/1535-7163.MCT-12-0015. Epub 2012 Jul 30.

8.

Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, Anderson ML, Lev D.

Clin Cancer Res. 2012 Sep 1;18(17):4633-45. doi: 10.1158/1078-0432.CCR-12-0436. Epub 2012 Jul 20.

9.

Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.

Ghadimi MP, Young ED, Belousov R, Zhang Y, Lopez G, Lusby K, Kivlin C, Demicco EG, Creighton CJ, Lazar AJ, Pollock RE, Lev D.

Clin Cancer Res. 2012 May 1;18(9):2545-57. doi: 10.1158/1078-0432.CCR-11-2592. Epub 2012 Mar 8.

10.

Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.

Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D, Lazar AJ.

Mod Pathol. 2012 Feb;25(2):212-21. doi: 10.1038/modpathol.2011.148. Epub 2011 Oct 21.

11.

Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target.

Colombo C, Creighton CJ, Ghadimi MP, Bolshakov S, Warneke CL, Zhang Y, Lusby K, Zhu S, Lazar AJ, West RB, van de Rijn M, Lev D.

J Pathol. 2011 Dec;225(4):574-82. doi: 10.1002/path.2951. Epub 2011 Aug 8.

PMID:
21826666
12.

Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.

Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D.

Clin Cancer Res. 2011 Sep 15;17(18):5901-12. doi: 10.1158/1078-0432.CCR-11-0660. Epub 2011 Aug 5.

13.

Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis.

Ghadimi MP, Al-Zaid T, Madewell J, Peng T, Colombo C, Hoffman A, Creighton CJ, Zhang Y, Zhang A, Lazar AJ, Pollock RE, Lev D.

Ann Surg Oncol. 2011 Dec;18(13):3762-70. doi: 10.1245/s10434-011-1794-0. Epub 2011 May 26.

PMID:
21614627
14.

Pleomorphic liposarcoma: clinical observations and molecular variables.

Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D.

Cancer. 2011 Dec 1;117(23):5359-69. doi: 10.1002/cncr.26195. Epub 2011 May 19.

15.

Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D.

Clin Cancer Res. 2011 Jun 15;17(12):3943-55. doi: 10.1158/1078-0432.CCR-11-0193. Epub 2011 May 3.

16.

Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178).

Ghadimi MP, Sanzenbacher R, Thiede B, Wenzel J, Jing Q, Plomann M, Borkhardt A, Kabelitz D, Janssen O.

FEBS Lett. 2002 May 22;519(1-3):50-8.

Supplemental Content

Loading ...
Support Center